scispace - formally typeset
T

Theodore L. Drell

Researcher at Witten/Herdecke University

Publications -  15
Citations -  1822

Theodore L. Drell is an academic researcher from Witten/Herdecke University. The author has contributed to research in topics: Cell migration & Metastasis. The author has an hindex of 14, co-authored 15 publications receiving 1721 citations.

Papers
More filters
Journal ArticleDOI

The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by β-blockers

TL;DR: This work contributes to the understanding of the basic cellular mechanisms of metastasis development, and delivers a rationale for the chemopreventive use of clinically established β‐blockers for the inhibition of metastases.
Journal ArticleDOI

Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters.

TL;DR: This work has shown that many types of neurotransmitter receptors are expressed on tumour cells, supporting the theory that psychosocial factors are involved in the progression of cancer, and could open up new avenues for chemoprevention of tumour-cell migration and metastatic development.
Journal ArticleDOI

Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells.

TL;DR: Evidence is provided for a strong regulatory involvement of neurotransmitters in the regulation of breast cancer cell migration, which might provide the basis for the use of the pharmacological agonists and antagonists for the chemopreventive inhibition of metastasis development.

Iconography : Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters

TL;DR: The most prominent regulatory factors are ligands to serpentine receptors-eg, chemokines and neurotransmitters as mentioned in this paper, which are involved in the migration of cancer cells into surrounding tissues, resulting in development of distant metastases.
Journal ArticleDOI

Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs.

TL;DR: induced migration, using MDA‐MB‐468 breast and PC‐3 prostate carcinoma cells, can be inhibited by using specific, clinically established receptor antagonists to the β2‐adrenoceptor, the D2 receptor, or the neurokinin‐1 receptor, respectively.